Evidence map›Paper›PMID 28716551›Full record

ReviewBone2018

Application of human induced pluripotent stem cells to model fibrodysplasia ossificans progressiva.

Emilie Barruet, Edward C Hsiao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Bone, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. ACVR1Bone · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Emilie BarruetDivision of Endocrinology and Metabolism, Department of Medicine and the Institute for Human Genetics, University of California, San Francisco, CA 94143, United States. Electronic address: Emilie.Barruet@ucsf.edu.
Edward C HsiaoDivision of Endocrinology and Metabolism, Department of Medicine and the Institute for Human Genetics, University of California, San Francisco, CA 94143, United States. Electronic address: Edward.Hsiao@ucsf.edu.
University of California, San Francisco · US

Funding

Innate immune regulation of stem cells in bone formationR01AR066735 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSIAO, EDWARD C · 2015 to 2019
$1.8M
NIAMS NIH HHS R01 AR066735
6 · The paper itself

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a genetic condition characterized by massive heterotopic ossification. FOP patients have mutations in the Activin A type I receptor (ACVR1), a bone morphogenetic protein (BMP) receptor. FOP is a progressive and debilitating disease characterized by bone formation flares that often occur after trauma. Since it is often difficult or impossible to obtain large amounts of tissue from human donors due to the risks of inciting more heterotopic bone formation, human induced pluripotent stem cells (hiPSCs) provide an attractive source for establishing in vitro disease models and for applications in drug screening. hiPSCs have the ability to self-renew, allowing researchers to obtain large amounts of starting material. hiPSCs also have the potential to differentiate into any cell type in the body. In this review, we discuss how the application of hiPSC technology to studying FOP has changed our perspectives on FOP disease pathogenesis. We also consider ongoing challenges and emerging opportunities for the use of human iPSCs in drug discovery and regenerative medicine.

Indexed as

Activin Receptors, Type IHumansInduced Pluripotent Stem CellsMutationOssification, HeterotopicSignal TransductionActivin Receptors, Type IACVR1 protein, humanActivin A type I receptorFibrodysplasia ossificans progressivaHuman disease modelsHuman induced pluripotent stem cells

Identifiers

PMID28716551
PMCPMC5767535
OpenAlexW2734630222

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.